Allergy Therapeutics PLC (LSE:AGY) - Overview

Stock Report

Allergy Therapeutics PLC AGY

Last Price
GBX19.75

Day Change
0.00|0.00%

As of 08/12/2016
15:59:17 GMT | GBX
Minimum 15 Minutes Delay.

Last Close19.75p
Day Range19.53 - 19.89
Mkt Cap117.20Mil
52-Wk Range17.25 - 32.60
Yield %0.00
ISINGB00B02LCQ05
Volume21,113
P/E-8.68
P/S2.32
P/CF-9.51

Share Price

Total Returns 08/12/2016

 Chg (%)  
More ...
Allergy Therapeutics PLC-7.60 
FTSE 100 TR GBP1.73
 
Financials
201420152016
More ...
Income Statement
Turnover41.9643.2348.51
Operating Profit1.210.73-11.95
Net Profit0.740.11-13.07
Reported EPS0.160.02-2.29
Balance Sheet
Current Assets14.2133.7937.61
Non Current Assets14.1916.9119.07
Total Assets28.4050.7056.68
Current Liabilities6.477.4212.52
Total Liabilities13.3216.2326.36
Total Equity15.0834.4730.32
Cash Flow
Operating Cash Flow2.332.48-11.54
Net Change in Cash1.0419.42-0.79
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-3.18-0.80--24.69---
2018-4.59-1.11--17.79---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
29/09/2016PurchaseMr. Peter Jensen19.2530,0005,775.00
27/09/2016PurchaseMr. Nick Wykeman17.75150,00026,625.00
26/09/2016PurchaseMr. Manuel Llobet18.00100,00018,000.00

Company Profile

Allergy Therapeutics PLC is engaged in the development, manufacturing, marketing and sale of pharmaceutical products designed for the immunological treatment of the allergic condition.
 

Sector

Drug Manufacturers - Major

Market Position

831 of 1865 Companies

Index

FTSE AIM All Share

Outlook

(26/09/2016) ceo - "We look forward to the future with confidence"

Next Event 08/03/2017

Next interim announcement
Ratios
CompSecMkt
More ...
PER (E)-21.1013.1215.86
Div Yld (E)0.004.254.26
PEG (E)0.000.200.15
ROCE-30.33209.39-30.49
Op Mrgn-24.73-16.09-33.54
EPS Grwth0.0010.0923.13
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr. Peter Jensen
Chief Executive OfficerMr. Manuel Llobet
Finance DirectorMr. Nick Wykeman
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2016 Morningstar. All rights reserved.